Summary

for people ages 18 years and up (full criteria)
at Irvine, California and other locations
study started
estimated completion

Description

Summary

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Official Title

A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease

Details

The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.

Keywords

Fabry Disease Lucerastat

Eligibility

You can join if…

Open to people ages 18 years and up

  1. Signed and dated ICF prior to any study-mandated procedure;
  2. Male or female adult subjects;
  3. FD diagnosis confirmed with local genetic test results;
  4. Fabry-associated neuropathic pain, as defined by the subject, in the last 3 months prior to screening;
  5. Enzyme replacement therapy (ERT) status:
  6. Subject never treated with ERT; or
  7. Subject has not received ERT for at least 6 months prior to screening; or
  8. Subject treated with ERT since at least 12 months at the time of the screening visit, and agreeing to stop ERT for approximately 8 months.
  9. A woman of childbearing potential is eligible only under certain conditions, e.g. taking contraceptive measures.
  10. Subjects with moderate or severe neuropathic pain during the screening period.

You CAN'T join if...

  1. Pregnant, planning to be become pregnant, or lactating subject.
  2. Severe renal insufficiency (eGFR < 30 mL/min/1.73 m2) at screening.
  3. Subject on regular dialysis for the treatment of chronic kidney disease.
  4. Known and documented transient ischemic attack, stroke, unstable angina, or myocardial infarction within 6 months prior to screening.
  5. Clinically significant unstable cardiac disease (e.g. uncontrolled symptomatic arrhythmia, congestive heart failure NYHA class III or IV).
  6. Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results.

Locations

  • University of California Irvine accepting new patients
    Irvine California 92696 United States
  • University of Utah - Division of Medical Genetics accepting new patients
    Salt Lake City Utah 84113 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Idorsia Pharmaceuticals Ltd.
ID
NCT03425539
Phase
Phase 3
Study Type
Interventional
Last Updated